• Peter J Hosein, Ana Echenique, Arturo Loaiza-Bonilla, Tatiana Froud, Katuzka Barbery, Caio M Rocha Lima, Jose M Yrizarry, and Govindarajan Narayanan.
• Department of Medicine and Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave., Suite 3400, Miami, FL 33136. Electronic address: phosein@med.miami.edu.
• J Vasc Interv Radiol. 2014 Aug 1;25(8):1233-1239.e2.

PurposeTo describe an initial experience with irreversible electroporation (IRE) in patients with colorectal liver metastasis (CLM).Materials And MethodsA retrospective analysis of patients undergoing IRE for the management of CLM was performed. Procedures were done percutaneously under general anesthesia. Patients were then followed for adverse events, tumor response, and survival.ResultsBetween March 2010 and February 2013, 29 patients underwent percutaneous ablation of 58 tumors in 36 IRE sessions. Most patients (89%) had an absolute or relative contraindication to thermal ablation. The median age was 62 years, and the median time from diagnosis to IRE was 28 months. The median number of lesions treated per patient was two, and the median tumor size was 2.7 cm. Patients had received previous chemotherapy regimens (range, 1-5 per patient). A new Metabolic Imaging And Marker Integration response evaluation criteria was used for response assessment, and was a predictor of progression-free and overall survival. The 2-year progression-free survival rate was 18% (95% confidence interval, 0%-35%), and the 2-year overall survival rate was 62% (95% confidence interval, 37%-87%). Complications included arrhythmias (n = 1) and postprocedure pain (n = 1). Both patients recovered without sequelae.ConclusionsPercutaneous IRE of CLM is feasible and safe. A new response evaluation system for colorectal cancer appears to be prognostic.Copyright © 2014 SIR. Published by Elsevier Inc. All rights reserved.

29 keywords...

hide…